Liraglutide Pen Injector

DRUG4 trials

Sponsors

Milton S. Hershey Medical Center, Zuyderland Medisch Centrum, University of North Carolina, Chapel Hill, Mayo Clinic

Conditions

Irritable Pouch SyndromeObesityObesity, MorbidOpiate Substitution TreatmentOpioid-Related DisordersPouchitisType 1 DiabetesType 2 Diabetes

Phase 1

Use of a GLP-1R Agonist to Treat Opioid Use Disorder

CompletedNCT04199728

Milton S. Hershey Medical CenterOpiate Substitution Treatment, Opioid-Related Disorders

Start: 2021-10-18End: 2023-09-13Updated: 2024-11-06

Phase 2

Efficacy of Liraglutide Therapy in Patients With IPAA

TerminatedNCT04763564

University of North Carolina, Chapel HillIrritable Pouch Syndrome, Pouchitis

Start: 2022-03-22End: 2023-10-16Updated: 2024-07-23

The Effect of Glycemic Control and of GLP-1 Receptor Agonism on Islet GLP-1 in People With Type 1 and Type 2 Diabetes

RecruitingNCT06976619

Mayo ClinicType 1 Diabetes, Type 2 Diabetes

Start: 2025-10-03End: 2029-03-31Target: 60Updated: 2025-10-14

Unknown Phase

Liraglutide for Low-responders After Bariatric Surgery

WithdrawnNCT04643301

Zuyderland Medisch CentrumObesity, Obesity, Morbid

Start: 2020-12-21End: 2021-12-31Updated: 2021-04-26

Related Papers

Ecological momentary assessment and cue-elicited drug craving as primary endpoints: study protocol for a randomized, double-blind, placebo-controlled clinical trial testing the efficacy of a GLP-1 receptor agonist in opioid use disorder

Addiction Science & Clinical Practice2024-07-276 citations